To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Exploring the Implications of New-Onset Diabetes in COVID-19: A Narrative Review
Cardiology, Native Cardio, Inc., Naples, USA.
Pain Management, NEMA Research, Inc., Naples, USA.
Pharmacy, Temple University, Philadelphia, USA.
Örebro University, School of Medical Sciences. Cardiology, Institution of Medical Sciences, Örebro University, Örebro, Sweden; Institute of Medicine, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2023 (English)In: Cureus, E-ISSN 2168-8184, Vol. 15, no 1, article id e33319Article, review/survey (Refereed) Published
Abstract [en]

Post-viral new-onset diabetes has been an important feature of the COVID-19 pandemic. It is not always clear if new-onset diabetes is the unmasking of a previously undiagnosed condition, the acceleration of prediabetes, or new-onset diabetes that would not have otherwise occurred. Even asymptomatic cases of COVID-19 have been associated with new-onset diabetes. Diabetes that emerges during acute COVID-19 infection tends to have an atypical presentation, characterized by hyperglycemia and potentially life-threatening diabetic ketoacidosis. It is not always clear if new-onset diabetes is type 1 or type 2 diabetes mellitus. Many cases of COVID-associated diabetes appear to be type 1 diabetes, which is actually an autoimmune disorder. The clinical course varies temporally and with respect to outcomes; in some cases, diabetes resolves completely or improves incrementally after recovery from COVID-19. Disruptions in macrophagy caused by COVID-19 infection along with an exaggerated inflammatory response that can occur in COVID-19 also play a role. Those who survive COVID-19 remain at a 40% elevated risk for diabetes in the first year, even if their case of COVID-19 was not particularly severe. A subsequent post-pandemic wave of new diabetes patients may be expected.

Place, publisher, year, edition, pages
Cureus Inc. , 2023. Vol. 15, no 1, article id e33319
Keywords [en]
Covid-19, covid-associated diabetes, diabetes, diabetes mellitus, type 3 diabetes
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:oru:diva-104051DOI: 10.7759/cureus.33319ISI: 001119651800013PubMedID: 36741600OAI: oai:DiVA.org:oru-104051DiVA, id: diva2:1734718
Available from: 2023-02-07 Created: 2023-02-07 Last updated: 2024-01-31Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Magnusson, Peter

Search in DiVA

By author/editor
Magnusson, Peter
By organisation
School of Medical Sciences
In the same journal
Cureus
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 22 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf